DEVV — Bioscience Neutraceuticals Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioscience Neutraceuticals, Inc., formerly JobLocationMap Inc., is a shell company. The Company is engaged in the development of visual job search service, which is focused on putting together job seekers and employers in JobLocationMap.com. Its Website intends to provide job seekers and employers with a platform to share their valid address and contact information to be shown as a pin on its provided map, manage their job description or their resume, and interact with a community of job searcher and employers from around the world. The Company is building an App for use with iPhone and Android. The App is focused on allowing users to search job listings to find a job location by map or use the App job search or browse jobs to find employment opportunities in an individual's area. The App seeks to connect people to job opportunities, Website global recruitment network, and to JobLocationMap platform.
Directors
- Last Annual
- December 31st, 2019
- Last Interim
- December 31st, 2019
- Incorporated
- June 15th, 2010
- Public Since
- December 9th, 2013
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 8,042,516
- Address
- 500 N Michigan Ave Ste 600, CHICAGO, 60611-3754
- Web
- Phone
- +1 7732368132
- Auditors
- B F Borgers CPA PC
Upcoming Events for DEVV
Similar to DEVV
1PM Industries
Pink Sheets on Nasdaq
3Dshopping.Com
Pink Sheets on Nasdaq
3 Sixty Risk Solutions
Pink Sheets on Nasdaq
Aardvark Ventures
Pink Sheets on Nasdaq
Access Worldwide Communications
Pink Sheets on Nasdaq
FAQ
As of Today at 01:03 UTC, shares in Bioscience Neutraceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Bioscience Neutraceuticals last closed at $0.00 and the price had moved by -99.67% over the past 365 days. In terms of relative price strength the Bioscience Neutraceuticals share price has underperformed the S&P500 Index by -99.61% over the past year.
There is no consensus recommendation for this security.
Bioscience Neutraceuticals does not currently pay a dividend.
Bioscience Neutraceuticals does not currently pay a dividend.
Bioscience Neutraceuticals does not currently pay a dividend.
To buy shares in Bioscience Neutraceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Bioscience Neutraceuticals had a market capitalisation of .
Here are the trading details for Bioscience Neutraceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: DEVV
Based on an overall assessment of its quality, value and momentum Bioscience Neutraceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioscience Neutraceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +10920.6%.
As of the last closing price of $0.00, shares in Bioscience Neutraceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioscience Neutraceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioscience Neutraceuticals' management team is headed by:
- Liang Chen - CEO